Farxiga (Dapagliflozin) Is Not Injected: How This Oral SGLT2 Inhibitor Actually Works

Why There Is No Farxiga Injection Technique

Dapagliflozin does not require injection because it is formulated as a film-coated oral tablet. Patients swallow the pill whole with water. No subcutaneous, intramuscular, or intravenous preparation of dapagliflozin exists on the market or in late-stage clinical development.

The confusion likely arises because dapagliflozin is frequently co-prescribed alongside injectable medications. Patients taking a GLP-1 receptor agonist such as semaglutide (Ozempic) or dulaglutide (Trulicity) by weekly subcutaneous injection may assume that all their diabetes or cardiometabolic drugs share the same route. They do not. The FDA-approved prescribing information for Farxiga specifies oral administration exclusively [1]. AstraZeneca has never filed an IND for an injectable formulation.

If your prescriber has added Farxiga to a regimen that already includes an injectable GLP-1 agonist or insulin, recognize that the Farxiga component is the tablet you swallow, while the injection applies to the other medication. Mixing up administration routes can lead to missed doses or incorrect technique for the drugs that do require injection.

How to Take Dapagliflozin Correctly

The correct administration technique for Farxiga is straightforward: swallow one tablet by mouth, once per day, with or without food. No needle, pen, or syringe is involved at any step.

The recommended starting dose for type 2 diabetes is 5 mg once daily, which may be increased to 10 mg if additional glycemic control is needed and the 5 mg dose is tolerated [1]. For heart failure and chronic kidney disease, the FDA-approved dose is 10 mg once daily from initiation, without a titration period [1]. Tablets should not be crushed or split. Patients who miss a dose should take it as soon as they remember, unless the next scheduled dose is approaching, in which case they skip the missed dose and resume normal timing.

Timing flexibility is a practical advantage. Unlike some medications requiring fasting-state dosing, dapagliflozin absorption is not clinically altered by food. A pharmacokinetic study published in Clinical Pharmacokinetics showed that a high-fat meal slightly delayed peak plasma concentration (Tmax) but did not meaningfully change overall exposure (AUC) [2]. Most patients find consistent morning dosing easiest to remember.

How Dapagliflozin Works: The SGLT2 Mechanism

Dapagliflozin blocks the sodium-glucose co-transporter 2 protein in the proximal tubule of the kidney, causing the body to excrete excess glucose through urine rather than reabsorbing it back into the bloodstream. This produces a measurable drop in blood sugar that is independent of insulin secretion.

Under normal physiology, the kidneys filter approximately 180 grams of glucose per day and reabsorb nearly all of it. SGLT2 accounts for roughly 90% of that reabsorption. By selectively inhibiting this transporter, dapagliflozin allows 60 to 80 grams of glucose per day to pass into the urine, which translates to an approximate caloric loss of 240 to 320 kcal daily [3]. This mechanism explains the mild weight loss (typically 2 to 3 kg) observed in clinical trials.

The glycosuric effect begins within hours of the first oral dose. A phase I study in healthy volunteers confirmed that urinary glucose excretion increases significantly by 6 hours post-dose and remains elevated for the full 24-hour dosing interval [2]. Because the mechanism does not depend on beta-cell function or insulin sensitivity, dapagliflozin retains efficacy even in patients with long-standing type 2 diabetes and significant beta-cell decline.

Beyond glucose lowering, SGLT2 inhibition produces osmotic diuresis and natriuresis. These effects reduce plasma volume and preload, which may partially explain the cardiovascular and renal benefits observed in large outcomes trials. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure now recommends SGLT2 inhibitors as a foundational therapy for heart failure with reduced ejection fraction, regardless of diabetes status [4].

The DAPA-HF Trial: Cardiac Benefits Without Injection

The landmark DAPA-HF trial established that oral dapagliflozin 10 mg significantly reduces cardiovascular events in heart failure patients. No injectable formulation was tested or needed to achieve these outcomes.

Published in the New England Journal of Medicine in 2019, DAPA-HF randomized 4,744 patients with heart failure and a left ventricular ejection fraction of 40% or less to receive dapagliflozin 10 mg or placebo, added to standard guideline-directed therapy [5]. The primary composite endpoint of worsening heart failure (hospitalization or urgent visit requiring IV therapy) or cardiovascular death occurred in 16.3% of the dapagliflozin group versus 21.2% of placebo. That 26% relative risk reduction (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) was consistent across prespecified subgroups, including patients without diabetes [5].

"The benefit of dapagliflozin was consistent irrespective of diabetes status," wrote lead investigator Dr. John McMurray in the trial publication [5]. This finding was key because it demonstrated that the cardiac benefits of SGLT2 inhibition are not simply downstream effects of glucose control. They reflect direct hemodynamic, metabolic, and possibly anti-fibrotic actions on the myocardium.

The trial's safety profile reinforced the tolerability of oral dosing. Rates of volume depletion, renal adverse events, and major hypoglycemia did not differ significantly between groups [5]. No injection-site reactions were reported because there were no injections.

DAPA-CKD: Renal Protection from a Tablet

Dapagliflozin also protects kidney function, and again the route is oral. The DAPA-CKD trial confirmed meaningful renal benefits across a broad chronic kidney disease population.

DAPA-CKD, published in the New England Journal of Medicine in 2020, enrolled 4,304 patients with an eGFR of 25 to 75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g [6]. The trial was stopped early for overwhelming efficacy. Dapagliflozin 10 mg reduced the composite of sustained eGFR decline of at least 50%, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [6].

The 2024 KDIGO guidelines for CKD management recommend SGLT2 inhibitors, including dapagliflozin, as first-line therapy for patients with CKD and albuminuria, citing the magnitude of renal protection and the favorable safety profile [7]. Dr. Hiddo Heerspink, the DAPA-CKD lead author, noted that "the renal and cardiovascular benefits were observed irrespective of the presence or absence of type 2 diabetes" [6]. That observation expanded the eligible patient population well beyond traditional diabetes care.

These renal benefits are achieved with the same 10 mg oral tablet used in other indications. No dose adjustment is required for patients with an eGFR of 25 mL/min/1.73 m² or above.

Comparing Oral Dapagliflozin to Actual Injectable Diabetes Drugs

Understanding where dapagliflozin fits relative to true injectables clarifies why the self-injection question misses the mark. Two major injectable classes exist in cardiometabolic care: GLP-1 receptor agonists and insulin.

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound) require weekly or daily subcutaneous injection using a prefilled pen. These drugs work by mimicking incretin hormones to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. Their injection technique involves selecting an injection site (abdomen, thigh, or upper arm), pinching the skin, inserting the needle at a 90-degree angle, and depressing the pen button.

Dapagliflozin shares none of these steps. It does share the therapeutic space. In fact, a 2021 meta-analysis in The Lancet Diabetes & Endocrinology of 764 trials found that SGLT2 inhibitors and GLP-1 receptor agonists both reduce major adverse cardiovascular events, but through different mechanisms and with complementary risk profiles [8]. The American Diabetes Association 2024 Standards of Care recommends considering both classes for patients with established cardiovascular disease or high cardiovascular risk, and notes that combining an oral SGLT2 inhibitor with an injectable GLP-1 agonist can address multiple pathophysiologic targets simultaneously [9].

Insulin, the other injectable class, requires careful dose titration, blood glucose monitoring, and injection technique training. Dapagliflozin's insulin-independent mechanism means it does not cause hypoglycemia when used as monotherapy, which is a significant practical advantage over injectable insulin.

Side Effects and Safety of Oral Dapagliflozin

The side effect profile of dapagliflozin reflects its oral route and renal mechanism. The most common adverse reactions are genital mycotic infections (yeast infections), occurring in approximately 5 to 7% of women and 2 to 3% of men, driven by the increased urinary glucose concentration that creates a favorable environment for Candida species [1].

Urinary tract infections occur slightly more frequently with dapagliflozin than placebo across trials, though the absolute difference is modest (approximately 1 to 2 percentage points) [1]. Volume depletion, presenting as dizziness or orthostatic hypotension, may affect patients on concurrent diuretics or those with low baseline blood pressure.

Diabetic ketoacidosis (DKA) is a rare but serious risk. The FDA issued a safety communication in 2015 warning that SGLT2 inhibitors can trigger euglycemic DKA, in which ketoacidosis develops with near-normal blood glucose levels [10]. Patients should be counseled to stop dapagliflozin during acute illness, before planned surgery, or if symptoms of ketoacidosis develop (nausea, vomiting, abdominal pain, fatigue, difficulty breathing). This risk is unrelated to injection technique because no injection is involved.

A pooled analysis of 13 phase IIb/III dapagliflozin trials (N=9,195) found no increased risk of bladder cancer, bone fractures, or liver injury compared with placebo, addressing earlier safety concerns that delayed some initial prescribing [11].

Who Should and Should Not Take Dapagliflozin

Dapagliflozin is FDA-approved for three distinct indications, all administered as an oral tablet. Patients with type 2 diabetes (as adjunct to diet and exercise), patients with heart failure with reduced ejection fraction (NYHA class II-IV, LVEF 40% or below), and patients with chronic kidney disease at risk of progression all qualify [1].

Contraindications include a history of serious hypersensitivity to dapagliflozin, patients on dialysis, and those with severe renal impairment for the diabetes indication specifically (eGFR <25 mL/min/1.73 m²) [1]. Dapagliflozin is not approved for type 1 diabetes in the United States due to the elevated DKA risk in this population.

Prescribers should assess kidney function before initiation and periodically thereafter. The 2024 ADA Standards of Care recommend monitoring eGFR and urine albumin at baseline and at least annually, with SGLT2 inhibitor therapy continued unless dialysis is initiated or the patient experiences intolerance [9].